Societal CDMO (SCTL) Stock Price, News & Analysis

Company Overview

Societal CDMO, Inc., a contract development and manufacturing organization, engages in the research and development, manufacturing, and packaging for various therapeutic dosage forms primarily in the small molecules in the United States and internationally. The company provides end-to-end services, such as formulation development focusing on complex formulations, reformulation, physical characterization, and excipient compatibility; analytical methods development which offers a range of analytical testing capabilities, including product testing, ICH stability, method development and validation, chromatography and spectroscopy equipment, stability chambers, and microbial testing; and pharmaceutical manufacturing that provides milling, blending, compression, spray and rotary granulation, particle and bead coating, encapsulation, liquids, lyophilization, and sterile fill and finish services. It also offers regulatory support, including handling communications with the food and drug administration (FDA) and seek consultation and guidance for client FDA meetings and responses; and pharmaceutical packaging and logistics, as well as smaller-scale primary and secondary packaging, labeling and kitting options suited for clinical trial materials and development packaging needs across dosage forms. The company was formerly known as Recro Pharma, Inc. and changed its name to Societal CDMO, Inc. in March 2022. Societal CDMO, Inc. was incorporated in 2007 and is based in Exton, Pennsylvania.

Key Stats

• Today's Range: $1.09 to $1.10
• 50-Day Range: $1.06 to $1.10
• 52-Week Range: $0.26 to $1.28
• Volume: 514,600 shs
• Average Volume: 957,342 shs
• Market Capitalization: $116.26 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

SCTL Stock Analysis - Frequently Asked Questions

How were Societal CDMO's earnings last quarter?

Societal CDMO, Inc. (NASDAQ:SCTL) issued its quarterly earnings results on Friday, March, 22nd. The company reported ($0.01) earnings per share (EPS) for the quarter. The firm earned $27.72 million during the quarter, compared to analysts' expectations of $25.50 million. Societal CDMO had a negative trailing twelve-month return on equity of 23.82% and a negative net margin of 14.03%.

What other stocks do shareholders of Societal CDMO own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Societal CDMO investors own include Applied DNA Sciences (APDN), Sunworks (SUNW), Meta Platforms (META), PayPal (PYPL), Avino Silver & Gold Mines (ASM), Avino Silver & Gold Mines (ASM) and Pfizer (PFE).

Company Calendar

• Last Earnings: 3/22/2024
• Today: 4/02/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:SCTL
• CIK: 1588972
• Web: www.recrocdmo.com
• Phone: (770) 534-8239
• Fax: 484-395-2471
• Employees: 258
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($0.15)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-13,270,000.00
• Net Margins: -14.03%
• Pretax Margin: -13.89%
• Return on Equity: -23.82%
• Return on Assets: -8.80%

Debt

• Debt-to-Equity Ratio: 0.01
• Current Ratio: 1.07
• Quick Ratio: 0.86

Sales & Book Value

• Annual Sales: $94.64 million
• Price / Sales: 1.23
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.56 per share
• Price / Book: 1.96

Miscellaneous

• Outstanding Shares: 105,691,000
• Free Float: 97,658,000
• Market Cap: $116.26 million
• Optionable: Optionable
• Beta: 1.61